Literature DB >> 19321255

Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.

Jia-Ning Zou1, Shu-Zhen Wang, Jia-Sen Yang, Xue-Gang Luo, Jing-Hang Xie, Tao Xi.   

Abstract

We previously reported that over-expression of SMYD3, a histone H3-K4 specific di- and tri-methyltransferase, plays a key role in cell viability, adhesion, migration and invasion. In this study, we investigated the mechanisms underlying these phenomena and found that knocking down SMYD3 expression in tumor cells significantly reduced the biological function of HGF and inhibited carcinoma cells migration and invasion. Due to the fact that the proto-oncogene c-Met encodes the high-affinity receptor for HGF, and the HGF-c-Met signaling plays a critical role in the tumor genesis, we further identified the partial correlation between SMYD3 and c-Met. The results showed that high expression of c-Met accompanied with over-expression of SMYD3. Silencing SMYD3 expression in tumor cells by specific shRNAs down-regulated c-Met gene transcription, while over-expressing SMYD3 induced c-Met transcription. Moreover, we demonstrated here that two SMYD3 binding sites within the c-Met core promoter region were significant in the transactivation of c-Met. The present findings provide significant insights into the epigenetic regulatory mechanisms of oncogene c-Met expression, and develop the strategies that may inhibit the progression of cancer migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321255     DOI: 10.1016/j.canlet.2009.02.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

1.  Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

2.  Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.

Authors:  Weiqi Fu; Nan Liu; Qi Qiao; Mingzhu Wang; Jinrong Min; Bing Zhu; Rui-Ming Xu; Na Yang
Journal:  J Biol Chem       Date:  2016-02-29       Impact factor: 5.157

3.  Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.

Authors:  Yong Liu; Honggen Liu; Xuegang Luo; Jingyu Deng; Yuan Pan; Han Liang
Journal:  Tumour Biol       Date:  2015-01-28

4.  SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.

Authors:  Claudio Fenizia; Cinzia Bottino; Silvia Corbetta; Raffaella Fittipaldi; Pamela Floris; Germano Gaudenzi; Silvia Carra; Franco Cotelli; Giovanni Vitale; Giuseppina Caretti
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

Review 5.  SET and MYND domain containing protein 3 in cancer.

Authors:  Lei Huang; A-Man Xu
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

6.  SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.

Authors:  Yong Liu; Xuegang Luo; Jingyu Deng; Yuan Pan; Li Zhang; Han Liang
Journal:  Tumour Biol       Date:  2014-12-04

7.  Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.

Authors:  Tian-nian Ren; Jing-song Wang; Yun-mian He; Chang-liang Xu; Shu-zhen Wang; Tao Xi
Journal:  Med Oncol       Date:  2010-10-19       Impact factor: 3.064

8.  Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.

Authors:  Krishna R Kalari; Scott J Hebbring; High Seng Chai; Liang Li; Jean-Pierre A Kocher; Liewei Wang; Richard M Weinshilboum
Journal:  BMC Genomics       Date:  2010-06-04       Impact factor: 3.969

9.  The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.

Authors:  Valentina Proserpio; Raffaella Fittipaldi; James G Ryall; Vittorio Sartorelli; Giuseppina Caretti
Journal:  Genes Dev       Date:  2013-06-01       Impact factor: 11.361

10.  A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.

Authors:  Alessia Peserico; Aldo Germani; Paola Sanese; Armenio Jorge Barbosa; Valeria Di Virgilio; Raffaella Fittipaldi; Edoardo Fabini; Carlo Bertucci; Greta Varchi; Mary Pat Moyer; Giuseppina Caretti; Alberto Del Rio; Cristiano Simone
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.